Know Cancer

forgot password

A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients

Phase 2
18 Years
Not Enrolling
Myelodysplastic Syndromes (MDS)

Thank you

Trial Information

A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients

LBH589 (20 mg PO) will be administered three times a week on Monday, Wednesday and Friday.
Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28
days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will
be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on
treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued
if there is evidence of disease progression, unacceptable toxicity and/or at the discretion
of the investigator.

Inclusion Criteria:

- Histologically or cytological documented diagnosis of myelodysplastic syndrome (MDS).

- Male or female patients aged >= 18 years old.

- MDS patients who have failed hypomethylating (azacitidine or decitabine) therapy.

- Patients with 5q-cytogenic abnormalities must also have progressed on or been
intolerant to lenalidomide.

- Patients with up to and including 30% blasts (FAB RAEB-T) will be eligible to enroll.

- CMML with >= 5% blasts will be eligible to enroll.

- ECOG PS 0, 1 or 2.

- Laboratory values must be as follows:

Bilirubin <= 1.5 mg/dL AST/SGOT <= 2.5 x ULN ALT/SGPT Creatinine <= 2.0 mg/dL or 24-hour
Creatinine Clearance >= 50 ml/min Albumin >= 3 g/dL Potassium >= lower limit normal (LLN)
Phosphorous >= LLN Calcium >= LLN Magnesium >= LLN

- Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to start of treatment.

- Life expectancy >= 12 weeks.

Exclusion Criteria:

- Prior treatment with an HDAC inhibitor.

- Prior intensive chemotherapy or high dose ara-C (>= 1 gm/m2)

- More than one prior single agent chemotherapy regimen. Prior hydroxyurea for
cytoreduction will be permitted however.

- Impaired cardiac function

- Active CNS disease, including leptomeningeal metastases.

- Unresolved diarrhea > CTCAE grade 1.

- Chemotherapy, investigational drug therapy, major surgery < 4 weeks prior to starting
study drug or patients that have not recovered from side effects of previous therapy.

- Patient is < 5 years free of another primary malignancy except if the other primary
malignancy is not currently clinically significant or requiring active intervention,
or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
situ. Existence of any other malignant disease is not allowed.

- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
not willing to use a double barrier method of contraception during the study and 3
months after the end of treatment. One of these methods of contraception must be a
barrier method.

- Male patients whose sexual partners are WOCBP not using a double method of
contraception during the study and 3 months after the end of treatment. One of these
methods must be a condom.

- Patients with gastrointestinal (GI) tract disease, causing the inability to take oral
medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation,
prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease
(e.g., Crohn's disease, ulcerative colitis).

- Other concurrent severe, uncontrolled systemic fungal, bacterial, viral or other
infection or intercurrent illness, including but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Patients with uncontrolled coagulopathy.

- Abnormal thyroid function (TSH or free T4) detected at screening. Patients with
known hypothyroidism who are stable on thyroid replacement are eligible.

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Response Rate (CR, Marrow CR + PR) of LBH in Patients With Relapsed or Refractory MDS.

Outcome Description:

Overall response rate (ORR) is defined by the modified International Working Group (IWG) Response Criteria for MDS. In the marrow, Complete Response (CR) is <= 5% blasts present with normal maturation of all cell lines. In peripheral blood, CR is defined as hemoglobin >= 11 g/dL, ANC >= 1000/mL, and platelets >= 100,000 with 0% blasts present. Partial Response (PR) is defined the same as CR with blasts decreased by >= 50% and >= 5% blasts in the marrow.

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

Ian W. Flinn, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

January 2008

Completion Date:

March 2012

Related Keywords:

  • Myelodysplastic Syndromes (MDS)
  • Myelodysplastic Syndromes (MDS)
  • Refractory
  • LBH589
  • Myelodysplastic Syndromes
  • Preleukemia



Florida Cancer Specialists Fort Myers, Florida  33901
Northeast Georgia Medical Center Gainesville, Georgia  30501
Consultants in Blood Disorders and Cancer Louisville, Kentucky  40207
Center for Cancer and Blood Disorders Bethesda, Maryland  20817
Tennessee Oncology, PLLC Clarksville, Tennessee  37043
Oncology Hematology Care Cincinnati, Ohio  45242
Chattanooga Oncology Hematology Associates Chattanooga, Tennessee  37404